Printer Friendly

Aastrom Biosciences begins study of new stem cell transplant procedure in leukemia patients.

Aastrom Biosciences, Inc., Ann Arbor, MI, has initiated a Phase I/II safety and feasibility study the rate of normal blood cell recovery and survival of leukemia patients following a transplant of cord blood stem cells using its new CB-II Therapy Kit in the AstromReplicell System. The company says the new kit has been shown to produce a significantly higher number of cord blood stem cells that its CB-I Therapy Kit.

As the use of cord blood stem cells to treat patients with leukemia and other diseases increases, Aastrom says there is concern about the comparatively small quantity of transplant cells available from standard cord blood cell collection procedures. The company says the Aastrom Replicell System, along with the CB-II Therapy Kit, has the potential to improve the availability, and hopefully the effectiveness, of cord blood stem cell transplants by increasing the amount of key therapeutic cells 10-fold.

An estimated 60,000 people are diagnosed with leukemia each year, and Aastrom believes about 35,000 are potential candidates for cord blood-derived stem cell transplants if a large enough cell dose is available.

Contact: Lisa Fern - (734) 930-5777, ext. 353
COPYRIGHT 2000 Transplant Communications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2000 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Comment:Aastrom Biosciences begins study of new stem cell transplant procedure in leukemia patients.
Publication:Transplant News
Article Type:Brief Article
Geographic Code:1USA
Date:Nov 30, 2000
Previous Article:Regeneration Technologies distributing new sports medicine allografts designed to cut operating room time.
Next Article:Orchid BioSciences launches innovative Web site to facilitate bone marrow transplant testing.

Related Articles
Aastrom awarded NIH grant for cord blood transplant program.
Aastrom enters distribution agreements with Gambro and Micromin to distribute AastromReplicell System.
Aastrom Biosciences, Loyola University perform first ever transplants of ex vivo produced stem cells in cancer patients.
Aastrom Biosciences initiates new product program for treatment of bone related diseases.
Aastrom Biosciences begins controlled clinical trial for cord blood therapy in leukemia patients.
Karmanos Cancer Institute, Aastrom Biosciences create new center for cell therapy.
Aastrom Biosciences receives orphan product designation from FDA for bone marrow stem cell product.
Aastrom Biosciences receives NIH grant to expand development of cell-base approaches for bone regeneration.
Aastrom received FDA approval to initiate multi-center trial for bone graft product.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |